Korean Pharma Companies Invest More In R&D and New Drug Development
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Address: 711, Royal Bldg 5 Dangju-dong, Jongro-gu, Seoul,Republic of Korea
Tel: +82 2 730 1451
Web: http://www.admRepublic of Korea.co.kr/
ADM Inc. is leader in providing full clinical services in Republic of Korea. ADM is a member of EPS group (HQ is located in Tokyo, www.eps.co.jp / www.eps-inter.com). If you consider Asian multi-national clinical study, ADM together with EPS will be the best choice.
Some of the services that we excell on providing are: Regulatory Strategy Consulting Registration Dossier IND Submission Communication with Regulatory Authorities Regulatory Change Reporting Phase I-IV Clinical Trial Project Planning Protocol and CRF Development Investigator Recruitment and Site Selection IRB Submission Investigational Staff Training Clinical Trial Management Monitoring Quality Control Quality Assurance Data Management Statistical Analysis Clinical Trial Report Writing Protocol & CRF Development IRB Submission Investigational Staff Training Project Management Data Collection and Monitoring Data Entry Data Management Statistical Analysis Safety Report Annual and Final Report Writing Data Management Plan Development Customized Database Design & Development Verification and Edits Medical Coding By MedDRA, WHO-ART, KIMs, Etc. Double Data Entry Full Electronic Audit Trail Data Comparison Query Generation and Resolution Data Transfer and Management Statistical Analysis Plan Development Statistical Programming and Validation Statistical Reports Statistical Consulting Project Master Files/ Essential Documents Audits Investigator Site Audits Sponsor Audits System Audits Pre-regulatory Inspection Audits, Including Preparation and Training for the Inspection Protocol Translation Informed Consent Form Translation Clinical Trial Report Translation IB Translation IRB Submission Document Translation All of Clinical Trial Document Translation
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Minister Moon discusses the results of his recent state visit to the Middle East with Korea’s President, and Korea’s assets and potential as a global healthcare partner in developing and…
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
See our Cookie Privacy Policy Here
